178 related articles for article (PubMed ID: 22768103)
1. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Chen MB; Zhu YQ; Xu JY; Wang LQ; Liu CY; Ji ZY; Lu PH
PLoS One; 2012; 7(6):e39655. PubMed ID: 22768103
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
3. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.
Chen MB; Wu XY; Yu R; Li C; Wang LQ; Shen W; Lu PH
PLoS One; 2012; 7(9):e45388. PubMed ID: 23049793
[TBL] [Abstract][Full Text] [Related]
4. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
5. Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.
Xu HY; Xu WL; Wang LQ; Chen MB; Shen HL
PLoS One; 2014; 9(4):e95371. PubMed ID: 24740294
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis.
Yang D; Chen MB; Wang LQ; Yang L; Liu CY; Lu PH
J Exp Clin Cancer Res; 2013 Dec; 32(1):105. PubMed ID: 24370277
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
[TBL] [Abstract][Full Text] [Related]
8. Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Szkandera J; Absenger G; Dandachi N; Regitnig P; Lax S; Stotz M; Samonigg H; Renner W; Gerger A
Mol Genet Genomics; 2012 Sep; 287(9):755-64. PubMed ID: 22903472
[TBL] [Abstract][Full Text] [Related]
9. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
10. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
11. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Bonnefoi H; Piccart M; Bogaerts J; Mauriac L; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Blot E; Zaman K; Cufer T; Lortholary A; Lidbrink E; André S; Litière S; Lago LD; Becette V; Cameron DA; Bergh J; Iggo R;
Lancet Oncol; 2011 Jun; 12(6):527-39. PubMed ID: 21570352
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.
Aas T; Geisler S; Eide GE; Haugen DF; Varhaug JE; Bassøe AM; Thorsen T; Berntsen H; Børresen-Dale AL; Akslen LA; Lønning PE
Eur J Cancer; 2003 Mar; 39(4):438-46. PubMed ID: 12751373
[TBL] [Abstract][Full Text] [Related]
13. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
14. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
15. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
16. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
17. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
18. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
19. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.
Sonnenberg M; van der Kuip H; Haubeis S; Fritz P; Schroth W; Friedel G; Simon W; Mürdter TE; Aulitzky WE
BMC Cancer; 2008 Dec; 8():364. PubMed ID: 19077243
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
